“Suicide Risk from 11 Anti-Epilepsy Drugs,” headlines blared across the country.
But we’re still here.
Was it sensationalism by the journalists, irresponsibility by the pharmaceutical industry or laxness of the FDA?
Posted in
Epilepsy,
Medication Issues,
ResearchTags:
anti-epilepsy drugs,
depakote,
depression,
FDA analysis,
Felbatol,
Gabitril,
Keppra,
Lamictal,
Lyrica,
Neurontin,
suicide risk,
Tegretol,
Topamax,
Trileptal,
Zonegran